An interventional study of Crest Cavity Protection Toothpaste and Experimental Mouthwash in Dental Plaque and Gingivitis, sponsored by HALEON. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by HALEON · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Dental Plaque with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dental Plaque · United States.
Among the 66 studies in Dental Plaque with a site in United States, this one is the 14th largest by enrollment of the 60 interventional ones that give a count, is one of 4 that started in 2025, is one of 34 with no phase, and was the 52nd registered.
354 studies on the registry are indexed under Dental Plaque; 60 are open to participants now.
Browse Dental Plaque studies →8 of the 66 studies in Dental Plaque with a site in United States are open now. Recruiting first, the newest first:
Flaus, Inc · Sites in United States
Ages 18–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–70
Lactea Therapeutics, LLC · Sites in United States
Ages 18–65 · Healthy volunteers
University of Nebraska · Sites in United States
Ages 19–85 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 18–85 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Dental Plaque studies recruiting now, 10 (29%) set no upper age limit and 20 (57%) stop at 75 or younger; 14 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 12 · Phase 4 4
First in 1998; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 138 is above the median of 55 across 317 interventional studies indexed under Dental Plaque.
Median enrollment 80 across the 60 interventional studies, 122 across the 6 observational. Of the 57 that completed or were terminated, 26 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 66 have an industry lead sponsor. The 10 most frequent:
HALEON is the lead sponsor of 65 studies on the registry; 10 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
HALEON has 9 studies filed under Dental Plaque — fewer than ten, so there is no comparison to draw.
4 of the studies in Dental Plaque with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07605338Phase 3Colgate PalmoliveTo Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis. | 2026-11 |
| NCT07706647The University of Texas Health Science Center at San AntonioOil Pulling Reduction | 2026-11-30 |
| NCT07902323Loma Linda UniversityEffect of Xylitol- Versus Erythritol-Sweetened Mints on Plaque ATP-Bioluminescence Readings | 2027-03 |
| NCT05384132University of Alabama at BirminghamNovel Dental Gel as an Adjunct to Scaling and Root Planing | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 66 studies in Dental Plaque with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this 12-week clinical study is to evaluate the ability of an experimental mouthwash, containing 0.085 percent (%) Cetylpyridinium chloride (CPC) as an adjunct to toothbrushing with a regular fluoride toothpaste, to improve gingival health and plaque accumulation compared to a regular fluoride toothpaste alone in participants with plaque-induced mild to moderate gingivitis.
This will be a single-center, 12-week, randomized, controlled, single blind (examiner only), 2-treatment arms, parallel group, stratified (by sex [male/female]) study, investigating gingival health and subgingival plaque reduction on healthy participants after twice daily using of an experimental mouthwash containing 0.085% weight/weight (w/w) CPC in combination with a commercially available regular toothpaste containing 0.243% w/w Sodium Fluoride (NaF) compared to a commercially available regular toothpaste containing 0.243% w/w NaF with no known anti-gingivitis nor anti plaque efficacy properties as control group. Approximately 132 participants (approximately 66 per group) will be randomized to ensure approximately 120 evaluable participants (approximately 60 per group) complete the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At screening (visit 1):
At baseline (visit 2; prior to dental prophylaxis)
Exclusion Criteria:
Medication exclusions: At screening (Visit 1):
Medication exclusions: At baseline (Visit 2):
Periodontal exclusions:
Dental exclusions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be instructed to brush their teeth with the toothpaste (Crest Cavity Protection) for at least one minute twice daily (morning and evening) for 12 weeks. After each brushing, participants will swish 20 milliliter (ml) of experimental mouthwash for 30 seconds without rinsing with water after use of mouthwash.
Drug: Crest Cavity Protection Toothpaste · Drug: Experimental Mouthwash
Participants will be instructed to brush their teeth with the toothpaste (Crest Cavity Protection) for at least one minute twice daily (morning and evening) for 12 weeks.
Drug: Crest Cavity Protection Toothpaste
Toothpaste containing 0.243% w/w NaF.
Mouthwash containing 0.085% w/w CPC.
Overall Number of Bleeding Sites (NBS) at Week 12 (Test Products Verses [vs.] Reference Product)
Gingival bleeding was assessed according to the Expanded Bleeding Index (EBI), by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.
Time frame: Week 12
Interproximal NBS at Week 12 (Test Products vs. Reference Product)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.
Time frame: Week 12
Overall NBS at Week 6 (Test Products vs. Reference Product)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.
Time frame: Week 6
Interproximal NBS at Week 6 (Test Products vs. Reference Product)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.
Time frame: Week 6
Mean Overall EBI at Week 6 and Week 12 (Test Products vs. Reference Product)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant was probed first (approximately 30 seconds) and gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0 equal to (=) no bleeding after 30 seconds, 1= bleeding observed within 30 seconds of probing, 2= bleeding observed immediately on probing. Lower score indicated improvement in the symptoms.
Time frame: Week 6 and Week 12
Mean Interproximal EBI at Week 6 and Week 12 (Test Products vs. Reference Product)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant was probed first (approximately 30 seconds) and gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0= no bleeding after 30 seconds, 1= bleeding observed within 30 seconds of probing, 2= bleeding observed immediately on probing. Lower score indicated improvement in the symptoms.
Time frame: Week 6 and Week 12
Mean Overall Modified Gingival Index (MGI) at Week 6 and Week 12 (Test Products vs. Reference Product)
The MGI assessment was a non-invasive evaluation which was focused on the visual symptoms of gingivitis (for example, redness, texture, edema). The MGI was assessed for all scorable teeth (second permanent molar to second permanent molar in each arch) by an appropriately qualified examiner using 5-point scoring system ranging from 0 to 4, where 0= Absence of inflammation, 1= Mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit, 2= Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms of gingivitis.
Time frame: Week 6 and Week 12
Mean Interproximal MGI at Week 6 and Week 12 (Test Products vs. Reference Product)
The MGI assessment was a non-invasive evaluation which was focused on the visual symptoms of gingivitis (for example, redness, texture, edema). The MGI was assessed for all scorable teeth (second permanent molar to second permanent molar in each arch) by an appropriately qualified examiner using 5-point scoring system ranging from 0 to 4, where 0= Absence of inflammation, 1= Mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit, 2= Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms of gingivitis.
Time frame: Week 6 and Week 12
Mean Overall Turesky Plaque Index (TPI) at Week 6 and Week 12 (Test Products vs. Reference Product)
The TPI was used to assess plaque on all gradable teeth. The plaque was disclosed using a plaque disclosing dye solution. TPI was assessed on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites). Disclosed plaque was scored using 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 millimeter \[mm\]) at the cervical margin, 3= Band of plaque wider than 1 mm but covering less than (\<) 1/3 of the tooth surface, 4= Plaque covering more than or equal to (\>=) 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement.
Time frame: Week 6 and Week 12
Mean Interproximal TPI at Week 6 and Week 12 (Test Products vs. Reference Product)
The TPI was used to assess plaque on all gradable teeth. The plaque was disclosed using a plaque disclosing dye solution. TPI was assessed on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites). Disclosed plaque was scored using 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \< 1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement.
Time frame: Week 6 and Week 12
This study was conducted at a single center in United States of America.
| Milestone | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) |
|---|---|---|
| Started | 68 | 68 |
| Completed | 65 | 66 |
| Not completed | 3 | 2 |
| Withdrew: Did not meet study criteria | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 |
Gingival bleeding was assessed according to the Expanded Bleeding Index (EBI), by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.
| bleeding sites | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) |
|---|---|---|
| Overall Number of Bleeding Sites (NBS) at Week 12 (Test Products Verses [vs.] Reference Product) | 8.9 ± 0.93 | 24.7 ± 0.93 |
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.
| bleeding sites | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) |
|---|---|---|
| Interproximal NBS at Week 12 (Test Products vs. Reference Product) | 5.2 ± 0.68 | 16.0 ± 0.67 |
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.
| bleeding sites | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) |
|---|---|---|
| Overall NBS at Week 6 (Test Products vs. Reference Product) | 9.5 ± 0.75 | 22.4 ± 0.75 |
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant were probed first (approximately 30 seconds) before recording the number of gingival units that bled. The NBS was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for assessment) with bleeding was observed immediately upon probing or within 30 seconds of probing.
| bleeding sites | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) |
|---|---|---|
| Interproximal NBS at Week 6 (Test Products vs. Reference Product) | 4.8 ± 0.55 | 13.1 ± 0.55 |
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant was probed first (approximately 30 seconds) and gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0 equal to (=) no bleeding after 30 seconds, 1= bleeding observed within 30 seconds of probing, 2= bleeding observed immediately on probing. Lower score indicated improvement in the symptoms.
| score on a scale | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) |
|---|---|---|
| Week 6 | 0.09 ± 0.008 | 0.22 ± 0.008 |
| Week 12 | 0.08 ± 0.009 | 0.23 ± 0.009 |
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degree, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. All scorable teeth in one quadrant was probed first (approximately 30 seconds) and gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0= no bleeding after 30 seconds, 1= bleeding observed within 30 seconds of probing, 2= bleeding observed immediately on probing. Lower score indicated improvement in the symptoms.
| score on a scale | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) |
|---|---|---|
| Week 6 | 0.07 ± 0.008 | 0.19 ± 0.008 |
| Week 12 | 0.07 ± 0.010 | 0.22 ± 0.010 |
The MGI assessment was a non-invasive evaluation which was focused on the visual symptoms of gingivitis (for example, redness, texture, edema). The MGI was assessed for all scorable teeth (second permanent molar to second permanent molar in each arch) by an appropriately qualified examiner using 5-point scoring system ranging from 0 to 4, where 0= Absence of inflammation, 1= Mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit, 2= Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms of gingivitis.
| score on a scale | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) |
|---|---|---|
| Week 6 | 1.13 ± 0.030 | 1.63 ± 0.030 |
| Week 12 | 1.18 ± 0.032 | 1.77 ± 0.032 |
The MGI assessment was a non-invasive evaluation which was focused on the visual symptoms of gingivitis (for example, redness, texture, edema). The MGI was assessed for all scorable teeth (second permanent molar to second permanent molar in each arch) by an appropriately qualified examiner using 5-point scoring system ranging from 0 to 4, where 0= Absence of inflammation, 1= Mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit, 2= Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms of gingivitis.
| score on a scale | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) |
|---|---|---|
| Week 6 | 1.28 ± 0.033 | 1.79 ± 0.033 |
| Week 12 | 1.32 ± 0.034 | 1.93 ± 0.034 |
The TPI was used to assess plaque on all gradable teeth. The plaque was disclosed using a plaque disclosing dye solution. TPI was assessed on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites). Disclosed plaque was scored using 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 millimeter \[mm\]) at the cervical margin, 3= Band of plaque wider than 1 mm but covering less than (\<) 1/3 of the tooth surface, 4= Plaque covering more than or equal to (\>=) 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement.
| score on a scale | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) |
|---|---|---|
| Week 6 | 2.83 ± 0.040 | 3.09 ± 0.040 |
| Week 12 | 2.67 ± 0.051 | 2.95 ± 0.051 |
The TPI was used to assess plaque on all gradable teeth. The plaque was disclosed using a plaque disclosing dye solution. TPI was assessed on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites). Disclosed plaque was scored using 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \< 1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement.
| score on a scale | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) |
|---|---|---|
| Week 6 | 3.08 ± 0.035 | 3.29 ± 0.035 |
| Week 12 | 2.92 ± 0.047 | 3.14 ± 0.047 |
Collected over Immediately after completion (signature) of the Informed Consent Form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test Products (Toothpaste + Mouthwash) | 0/68 (0%) | 0/68 (0%) | 8/68 (11.8%) |
| Reference Product (Toothpaste) | 0/68 (0%) | 0/68 (0%) | 4/68 (5.9%) |
| Event | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) |
|---|---|---|
| Tooth DiscolourationGastrointestinal disorders | 7/68 | 0/68 |
| Aphthous UlcerGastrointestinal disorders | 0/68 | 3/68 |
| Burn Oral CavityInjury, poisoning and procedural complications | 0/68 | 1/68 |
| Skin ExfoliationSkin and subcutaneous tissue disorders | 1/68 | 0/68 |
The Safety population included all randomized participants who received at least one dose of investigational product.
| Age, Continuous(years) | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) | Total |
|---|---|---|---|
| Mean | 55.2 ± 13.42 | 52.3 ± 14.90 | 53.7 ± 14.21 |
| Sex: Female, Male(Participants) | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) | Total |
|---|---|---|---|
| Female | 38 | 37 | 75 |
| Male | 30 | 31 | 61 |
| Ethnicity (NIH/OMB)(Participants) | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 4 |
| Not Hispanic or Latino | 65 | 67 | 132 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Test Products (Toothpaste + Mouthwash) | Reference Product (Toothpaste) | Total |
|---|---|---|---|
| African American/African Heritage | 5 | 8 | 13 |
| Asian - East Asian Heritage | 0 | 2 | 2 |
| Asian - South East Asian Heritage | 0 | 1 | 1 |
| White - Arabic/North African Heritage | 0 | 1 | 1 |
| White - White/Caucasian/European Heritage | 63 | 56 | 119 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trialregister@haleon.com.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.
Ran from Apr 2025 to primary completion in Aug 2025, 3 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 45 industry-sponsored interventional studies with no phase under Dental Plaque, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 3 months is above that.
Counting every sponsor, half of 179 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.